Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1633 1652 1653 1656 1699
This examiner grants 57% of resolved cases
George Themistoclis Lountos works in Tech Center 1600 and Art Unit 1633. The data for 7 resolved cases shows an allowance rate of 57.1 percent. This 57.1 percent rate indicates the level of success for applicants in this unit. The 7 resolved cases provide an initial look at the examiner's performance metrics in Tech Center 1600.
The interview lift is 60.0 percent. This 60.0 percent lift is very high, suggesting that interviews are an extremely effective tool for moving cases toward an allowance. Even with only 7 resolved cases, the 60.0 percent lift is a strong signal for practitioners. This lift is a significant addition to the 57.1 percent baseline allowance rate.
The median days to allowance is 1245. This 1245-day timeline is the typical timeframe for cases that reach a grant. With 7 resolved cases, these metrics provide a perspective on the prosecution trends for Lountos in Art Unit 1633. The 1245-day figure serves as a benchmark for expected pendency for successful applications.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18866357 | MICROORGANISM WITH WEAKENED GLUCONATE REPRESSOR PROTEIN ACTIVITY AND METHOD FOR PRODUCING L-ARGININE BY USING SAME | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 18725546 | NOVEL MICROORGANISM, NOVEL MICROORGANISM CULTURE OR EXTRACT, AND ERGOTHIONEINE PRODUCTION METHOD | Non-Final OA | National Institute Of Advanced Industrial Science And Technology |
| 18786977 | Bst DNA POLYMERASE, REAGENT COMPOSITION, AND NUCLEIC ACID AMPLIFICATION METHOD | Non-Final OA | Sysmex Corporation |
| 18442665 | METHOD FOR PURIFYING PROTEINS | Non-Final OA | AMGEN INC. |
| 18728493 | GLYCOSIDE HYDROLASE AND/OR TRANSGLYCOSYLASE FOR SYNTHESIS OF XYLOSE OLIGOSACCHARIDES | Non-Final OA | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
| 18719350 | NOVEL PROMOTER | Non-Final OA | KAO CORPORATION |
| 18685684 | FRAGRANCE BEAD COMPOSITION AND USE THEREOF | Non-Final OA | Novozymes A/S |
| 18040866 | Vesicle Targeting Proteins And Uses Of Same | Non-Final OA | Amicus Therapeutics, Inc. |
| 17767425 | MONO-HYDROXY OR DI-HYDROXY DERIVATIVES OF POLYUNSATURATED FATTY ACIDS, PRODUCTION METHOD THEREFOR, AND USE THEREOF | Final Rejection | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy